Stock market today: S&P 500 hits fresh record close on stronger economic growth
Investing.com - Stifel raised its price target on Supernus Pharmaceuticals (NASDAQ:SUPN) to $43.00 from $38.00 on Wednesday, while maintaining a Hold rating on the stock. According to InvestingPro data, the stock is currently trading near its 52-week high, with a market capitalization of $2.66 billion.
The price target increase follows Supernus’s strong second-quarter 2025 performance, with revenues of $165.5 million exceeding consensus estimates of $154.1 million. The company’s growth was primarily driven by increasing traction with its Qelbree and Gocovri products, supported by impressive gross profit margins of 88.53%.
Supernus has recently diversified its portfolio with the approval of Onapgo pump for severe Parkinson’s disease, completing its movement disorder offerings. The company also closed its acquisition of SAGE for Zurzuvae, a treatment for post-partum depression. InvestingPro analysis reveals 12+ additional insights about SUPN’s growth potential and financial health.
Following the SAGE acquisition, Supernus updated its fiscal year 2025 guidance, raising revenue expectations to $670-700 million from the previous $600-630 million range. The company maintained its non-GAAP operating income guidance at $105-135 million.
Supernus reported cash holdings of $522.6 million, with approximately $240-260 million on a pro forma basis, which Stifel believes positions the company well for continued investment in both products and pipeline development.
In other recent news, Supernus Pharmaceuticals reported its second-quarter 2025 earnings, showing a mixed financial performance. The company’s revenue reached $165 million, exceeding the forecast of $154.3 million by 7.26%. However, earnings per share (EPS) were $0.40, falling short of the anticipated $0.48 by 16.67%. These results highlight a divergence between revenue growth and profit expectations. Despite the earnings miss, the revenue beat is notable for investors keeping an eye on the company’s financial health. Analyst firms have not provided any recent upgrades or downgrades, leaving the focus on Supernus’s earnings performance. Investors may find these developments significant when considering the company’s future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.